137 related articles for article (PubMed ID: 9117214)
1. The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumour Antigen Study Group.
Br J Urol; 1997 Mar; 79(3):362-6. PubMed ID: 9117214
[TBL] [Abstract][Full Text] [Related]
2. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
3. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
[TBL] [Abstract][Full Text] [Related]
4. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
5. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA
Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
[TBL] [Abstract][Full Text] [Related]
7. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
Gregersen B; Mommsen S; Svanholm H
Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792
[TBL] [Abstract][Full Text] [Related]
8. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
Leyh H; Mazeman E
Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
10. The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer.
Kirollos MM
Br J Urol; 1998 May; 81(5):781-2. PubMed ID: 9634071
[No Abstract] [Full Text] [Related]
11. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
12. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
13. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of BTA stat test, NMP-22, and cytology in the diagnosis of bladder cancer].
Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juarez F; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; de Diego Rodríguez E; Radó Velázquez MA
Arch Esp Urol; 2000; 53(1):21-7. PubMed ID: 10730421
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
16. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive detection of bladder cancer with the BTA stat test.
Pode D; Shapiro A; Wald M; Nativ O; Laufer M; Kaver I
J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
Leyh H; Hall R; Mazeman E; Blumenstein BA
Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
[TBL] [Abstract][Full Text] [Related]
19. The role of nuclear matrix protein 22 combined with bladder tumor antigen stat test in surveillance of recurring bladder cancer.
Xu K; Tam PC; Hou S; Wang X; Bai W
Chin Med J (Engl); 2002 Nov; 115(11):1736-8. PubMed ID: 12609098
[TBL] [Abstract][Full Text] [Related]
20. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
